SALT LAKE CITY, February 20, 2019 – Recursion, a clinical-stage biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2019. The list honors the businesses making the most profound impact on both industry and culture, showcasing a variety of ways to thrive in today’s volatile world. Founded in 2013, Recursion is an industry leader in applying AI to drug discovery and has created an innovative culture that brings together data science, engineering and drug discovery teams. The company has already achieved partnerships with leading pharmaceutical companies such as Sanofi and Takeda, and has advanced two programs into clinical development.
“Our ability to innovate is directly tied to the strength of our interdisciplinary teams. We’ve been able to bring together engineers, biologists, data scientists, and chemists to build the most advanced drug discovery teams in the industry.” said Chris Gibson, Ph.D., co-founder and CEO of Recursion. “They are working side-by-side to reimagine the drug discovery process from start to finish and they continue to find potential medicines for dozens of human conditions.”